Posted by Michael Wonder on 18 Feb 2023
FDA approves Syfovre (pegcetacoplan injection) as the first and only treatment for geographic atrophy, a leading cause of blindness
17 February 2023 - Approved for all patients with geographic atrophy, with dosing flexibility every 25 to 60 days.
Apellis Pharmaceuticals today announced that the US FDA has approved Syfovre (pegcetacoplan injection) for the treatment of geographic atrophy secondary to age-related macular degeneration.
